Your browser doesn't support javascript.
loading
Whole genome and exome sequencing reference datasets from a multi-center and cross-platform benchmark study.
Zhao, Yongmei; Fang, Li Tai; Shen, Tsai-Wei; Choudhari, Sulbha; Talsania, Keyur; Chen, Xiongfong; Shetty, Jyoti; Kriga, Yuliya; Tran, Bao; Zhu, Bin; Chen, Zhong; Chen, Wanqiu; Wang, Charles; Jaeger, Erich; Meerzaman, Daoud; Lu, Charles; Idler, Kenneth; Ren, Luyao; Zheng, Yuanting; Shi, Leming; Petitjean, Virginie; Sultan, Marc; Hung, Tiffany; Peters, Eric; Drabek, Jiri; Vojta, Petr; Maestro, Roberta; Gasparotto, Daniela; Kõks, Sulev; Reimann, Ene; Scherer, Andreas; Nordlund, Jessica; Liljedahl, Ulrika; Foox, Jonathan; Mason, Christopher E; Xiao, Chunlin; Hong, Huixiao; Xiao, Wenming.
Afiliação
  • Zhao Y; Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. Yongmei.Zhao@nih.gov.
  • Fang LT; Bioinformatics Research & Early Development, Roche Sequencing Solutions Inc., Belmont, CA, USA.
  • Shen TW; Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Choudhari S; Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Talsania K; Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Chen X; Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Shetty J; Sequencing Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Kriga Y; Sequencing Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Tran B; Sequencing Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Zhu B; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Chen Z; Center for Genomics, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
  • Chen W; Center for Genomics, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
  • Wang C; Center for Genomics, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
  • Jaeger E; Core Applications Group, Product Development, Illumina Inc, Foster City, CA, USA.
  • Meerzaman D; Computational Genomics and Bioinformatics Branch, Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Lu C; AbbVie Genomics Research Center, North Chicago, IL, USA.
  • Idler K; AbbVie Genomics Research Center, North Chicago, IL, USA.
  • Ren L; State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Zheng Y; State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Shi L; State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Petitjean V; Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Sultan M; Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Hung T; Companion Diagnostics Development, Oncology Biomarker Development, Genentech, South San Francisco, CA, USA.
  • Peters E; Companion Diagnostics Development, Oncology Biomarker Development, Genentech, South San Francisco, CA, USA.
  • Drabek J; IMTM, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
  • Vojta P; Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands.
  • Maestro R; IMTM, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
  • Gasparotto D; Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands.
  • Kõks S; Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands.
  • Reimann E; Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, National Cancer Institute, Unit of Oncogenetics and Functional Oncogenomics, Aviano, Italy.
  • Scherer A; Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands.
  • Nordlund J; Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, National Cancer Institute, Unit of Oncogenetics and Functional Oncogenomics, Aviano, Italy.
  • Liljedahl U; Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands.
  • Foox J; Perron Institute for Neurological and Translational Science, Nedlands, Australia.
  • Mason CE; Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia.
  • Xiao C; Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands.
  • Hong H; Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.
  • Xiao W; Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands.
Sci Data ; 8(1): 296, 2021 11 09.
Article em En | MEDLINE | ID: mdl-34753956
With the rapid advancement of sequencing technologies, next generation sequencing (NGS) analysis has been widely applied in cancer genomics research. More recently, NGS has been adopted in clinical oncology to advance personalized medicine. Clinical applications of precision oncology require accurate tests that can distinguish tumor-specific mutations from artifacts introduced during NGS processes or data analysis. Therefore, there is an urgent need to develop best practices in cancer mutation detection using NGS and the need for standard reference data sets for systematically measuring accuracy and reproducibility across platforms and methods. Within the SEQC2 consortium context, we established paired tumor-normal reference samples and generated whole-genome (WGS) and whole-exome sequencing (WES) data using sixteen library protocols, seven sequencing platforms at six different centers. We systematically interrogated somatic mutations in the reference samples to identify factors affecting detection reproducibility and accuracy in cancer genomes. These large cross-platform/site WGS and WES datasets using well-characterized reference samples will represent a powerful resource for benchmarking NGS technologies, bioinformatics pipelines, and for the cancer genomics studies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Genoma Humano / Sequenciamento Completo do Genoma / Sequenciamento do Exoma / Neoplasias Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Sci Data Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Genoma Humano / Sequenciamento Completo do Genoma / Sequenciamento do Exoma / Neoplasias Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Sci Data Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos